Navigation Links
Breathable treatment to help prevent asthma attacks
Date:8/31/2012

Details of a treatment that could help asthmatics fight infections that trigger 80% of asthma attacks, developed by University of Southampton spin-out company Synairgen, will be presented to European respiratory experts on Sunday 2 September.

The study provides the first evidence that boosting asthmatics' immune systems can help reduce the number of asthma attacks due to the common cold and other viral infections for the 5.4 million asthmatics in the UK.

Professor Ratko Djukanovic, a respiratory specialist at the University of Southampton and Southampton General Hospital, led the study and will present findings to the European Respiratory Society's annual congress in Vienna.

He says: "We have demonstrated the potential of a treatment, simply breathed in by the patient, which significantly reduces worsening of asthma symptoms and the patient's need to use their asthma inhaler in response to common cold infection. By presenting an immune system protein molecule, interferon beta, to the patient's lungs we can prime their body to challenge infections more effectively."

Professor Djukanovic directs the National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit, one of 20 sites involved in the trial and a partnership between the University of Southampton and University Hospital Southampton NHS Foundation Trust, funded by NIHR.

He continues: "Southampton researchers, working alongside asthma patients, made the original discovery that weakened immunity amongst asthmatics was key to viral impacts; now study participants are helping us to confirm that discovery and translate it into treatments for their, and other asthmatic patients', benefit through the work of the unit."

Professor Stephen Holgate CBE, leading international asthma specialist at the University of Southampton and founder of Synairgen, says: "This is a really promising breakthrough for the future treatment of asthma and one of the most exciting developments that I have seen in years. These impressive findings across different endpoints, together with the accumulating body of evidence we have generated for other respiratory viruses such as influenza (Swine and Bird flu) and respiratory syncytial virus (RSV), strongly suggest that inhaled interferon beta has the potential to be used as a powerful broad spectrum antiviral respiratory drug in lung diseases such as COPD and pandemic flu."

Richard Marsden, Chief Executive of Synairgen, adds: "This is a great result for the development of our programme. To put this treatment's potential into context, it is estimated that in the US alone there are some 2 to 4 million difficult to treat (Step 4 and 5) adult asthma sufferers who could benefit from this therapy. We continue to analyse the wealth of data generated by this important trial and to plan the next phase of its development, ideally alongside an industry partner."


'/>"/>

Contact: Becky Attwood
r.attwood@soton.ac.uk
44-023-805-95457
University of Southampton
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Clinical insight improves treatment with new lung cancer drug
3. Rapid Asthma Treatment in ER May Prevent Admission
4. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
5. Breast cancer patients suffer treatment-related side effects long after completing care
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. Mobile Stroke Units Might Trim Time to Treatment
8. Breast Cancer Treatment Side Effects May Last for Years
9. Mouse Study Hints at New Path for Diabetes Treatment
10. Symptomatic behaviour in childhood strongly predicts psychiatric treatment as a young adult
11. Exercise improves quality of life during breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... flexibility in repaying their loans, more information about their loan terms and accounts, ... outstanding student loan debt, including federal and private loans, has reached $1.3 trillion, ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering the many ... learn more about the options currently available to them and which ones might work ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Dairy Products, Inc. in an upcoming episode, airing third quarter 2016 via Discovery ... churning cream into butter, Grassland Dairy Products, located in Greenwood, Wisconsin applies product ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... to promote their animal line of probiotics, Petbiotics ™, as they fondly ... turnout of animal rescue groups networking for their non-profit organizations. Animal rescues across ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
(Date:4/28/2016)... 2016 Dr. Vivek Ahuja , ... Ste phen Schmidt ... provider of cloud-based software solutions for life sciences, today announced key ... a wealth of insight to a growing business.  This will bolster ... George Phillips joined ArisGlobal in the position of Vice ...
(Date:4/28/2016)... 28, 2016 TapImmune,Inc. (TPIV), ... peptide and gene-based immunotherapeutics and vaccines for the treatment of ... at the 3rd Annual Growth Capital Expo to ... 2016 at Caesars Palace in Las Vegas, Nevada.  The ... May 4 th by Dr. John N. Bonfiglio ...
Breaking Medicine Technology: